Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 1913

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 13
Chunk 1913
---
 209,440 

    Cash and Investments held in trust 
     9,021,005  
     50,477,963 
  
    Total assets 
    $9,037,873  
    $50,687,403 

    Liabilities and Shareholders’ Deficit 

    Accounts Payable and accrued offering costs and expenses 
    $4,640,414  
    $3,749,581 
  
    Accrued interest expense -related party 
     74,555  
     18,021 
  
    Accrued interest expense - others 
     58,586  
     18,878 
  
    Promissory Note - related party 
     1,423,237  
     842,500 
  
    Promissory Note - Others 
     1,350,292  
     975,000 
  
    Total current liabilities 
     7,547,084  
     5,603,980 

    Deferred underwriter compensation 
     2,887,500  
     2,887,500 
  
    Total liabilities 
     10,434,584  
     8,491,480 

    Commitments and contingencies 

    Class A ordinary shares subject to possible redemption 751,837 and 4,537,829 shares at redemption value of $12.00 and $11.12 per share as of December 31, 2024 and 2023, respectively 
     9,021,005  
     50,477,963 

    Shareholders’ Deficit: 

    Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding 
     -  
     - 
  
    Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized, 510,000 shares issued and outstanding (excluding 751,837 and 4,537,829 shares subject to possible redemption as of December 31, 2024 and 2023, respectively subject to possible redemption) 
     51  
     51 
  
    Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized, 2,062,500 shares issued and outstanding 
     206  
     206 
  
    Accumulated deficit